Search clinical trials for: Fluorine F 18 rhPSMA-7.3

Total 560 results

M.D. Anderson Cancer Center

Recruiting

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma | Localized Prostate Carcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
Emory University
National Cancer Institute (NCI); Blue Earth Diagnostics

Active, not recruiting

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma

United States
Mayo Clinic

Not yet recruiting

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
National Cancer Institute (NCI)

Completed

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Metastatic Malignant Neoplasm in the Bone | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma

United States
Stanford University

Terminated

Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer

Bone Cancer

United States
University of Wisconsin, Madison
Millennium Pharmaceuticals, Inc.

Terminated

NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis

Prostatic Neoplasms | Prostate Cancer

United States
University Hospitals Cleveland Medical Center

Completed

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

F18-MHF: Orthopedic Implants-Associated Infection Detection

Knee Disease | Knee Infection

United States
ABX advanced biochemical compounds GmbH

Completed

F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

Prostate Cancer | Prostate Cancer Recurrent

France
The Cleveland Clinic
Avid Radiopharmaceuticals

Terminated

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Cardiac Amyloidosis

United States
Jonsson Comprehensive Cancer Center

Terminated

Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

Lung Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas

Brain and Central Nervous System Tumors

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer

Recurrent Prostate Cancer

United States
University Health Network, Toronto

Completed

FCH PET/MRI Parathyroid Localization

Hyperparathyroidism, Primary | Positron-Emission Tomography | 18F-fluorocholine

Canada
University of Alabama at Birmingham

Recruiting

18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study

Prostate Cancer

United States
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Terminated

Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer

Cervical Cancer

United States
Insel Gruppe AG, University Hospital Bern

Completed

Diagnostic Accuracy and Performance of 18F-PSMA-1007

Prostate Cancer

Switzerland
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer

Prostate Carcinoma

United States
Blue Earth Diagnostics
Parexel

Completed

Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

Prostate Cancer

United States, Finland, Netherlands
Vanderbilt-Ingram Cancer Center

Completed

PET Study in Patients With Non-Hodgkin Lymphoma

Lymphoma

United States
Blue Earth Therapeutics Ltd
PSI CRO

Recruiting

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Urogenital Neoplasms | Prostatic Neoplasms | Prostatic Diseases | Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

United States, Netherlands
Blue Earth Diagnostics
Parexel

Completed

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)

Prostate Cancer

United States, Finland, Germany, Netherlands
Blue Earth Diagnostics

Completed

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Prostate Cancer

Finland
Stanford University
National Cancer Institute (NCI)

Terminated

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Hormone-Resistant Prostate Cancer

United States
University Hospital, Caen

Unknown

Imaging of Unstable Carotid Plaque in Patient Referred to Endarterectomy (CAROTEP)

Carotid Artery Stenosis

France
University of California, Davis
National Cancer Institute (NCI); CellSight Technologies, Inc.

Withdrawn

[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma
Chang Gung Memorial Hospital

Completed

Novel Neuroimage Study in Tauopathies With Parkinsonism

Parkinsonism

Taiwan
Siemens Molecular Imaging
Fudan University

Completed

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

Head and Neck Cancer | Lung Cancer | Liver Cancer

China
MidLantic Urology
Blue Earth Diagnostics

Recruiting

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Prostate Cancer

United States
Chang Gung Memorial Hospital

Completed

18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls

Frontotemporal Dementia | Progressive Supranuclear Palsy | Alzheimer's Disease | Vascular Cognitive Impairment | Cortical Basal Syndrome

Taiwan
AHS Cancer Control Alberta

Recruiting

A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

Prostate Cancer | Oncology

Canada
University of Washington
National Cancer Institute (NCI)

Terminated

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Recurrent Breast Carcinoma | Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
John M. Buatti
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

Uterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus Neoplasms

United States
Siemens Molecular Imaging

Completed

Exploratory and Safety Study of [F-18]W372

Alzheimer's Disease

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
CHEOL WHAN LEE, MD, PhD.

Terminated

Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina

Coronary Artery Diseases

Korea, Republic of
Northwell Health

Completed

Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

Neuroendocrine Tumors

United States
Siemens Molecular Imaging

Completed

A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation (FLT101)

Head and Neck Cancer | Lung Cancer

United States
University of Washington

Active, not recruiting

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Primary or Recurrent Breast Carcinoma

United States
Chang Gung Memorial Hospital

Completed

Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)

Major Depressive Disorder

Taiwan
National Cancer Institute (NCI)

Completed

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
Brigham and Women's Hospital

Terminated

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

Cardiac Amyloidosis

United States
National Cancer Institute (NCI)

Completed

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

Recurrent Prostate Cancer | Bone Metastases | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
University Medical Center Groningen

Recruiting

Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer (MIMETIC)

Medullary Thyroid Cancer | Thyroid Cancer, Medullary | Medullary Thyroid Carcinoma | Thyroid Carcinoma, Medullary

Netherlands
OHSU Knight Cancer Institute
Oregon Health and Science University; Progenics Pharmaceuticals, Inc.

Not yet recruiting

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Prostate Adenocarcinoma | Castration Resistant Prostate Cancer | Castration Sensitive Prostate Cancer

United States
Brigham and Women's Hospital

Completed

Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA

MSA

United States
Avid Radiopharmaceuticals

Completed

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation

Alzheimer Disease

United States

Search clinical trials for: Fluorine F 18 rhPSMA-7.3

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations